MCDA criteria | Indication uniqueness | Disease rarity | Disease severity | Adv.tech. | Manufacturing technology | Therapeutic alternative | Sci. evid. Clin.eff | Benefits from use of medicine (safety aspects) | Cost effectiveness analysis | Budget impact analysis | Therapy cost | HTA recommendations issued elsewhere | Rationalization analysis | Weight |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indication uniqueness | 0.024540349 | 0.014020913 | 0.014608234 | 0.014867258 | 0.014915032 | 0.015760303 | 0.017901509 | 0.020706096 | 0.023441153 | 0.026396161 | 0.031745601 | 0.03841396 | 0.042687007 | 2.31% |
Disease rarity | 0.058466036 | 0.033404057 | 0.019141824 | 0.019481235 | 0.019543835 | 0.020651432 | 0.023457149 | 0.027132126 | 0.030715994 | 0.034588072 | 0.041597684 | 0.050335534 | 0.055934698 | 3.34% |
Disease severity | 0.053850296 | 0.055939809 | 0.032055685 | 0.017943243 | 0.018000901 | 0.019021056 | 0.021605269 | 0.024990116 | 0.028291047 | 0.031857435 | 0.038313656 | 0.046361676 | 0.051518801 | 3.38% |
Adv.tech. | 0.00615432 | 0.006393121 | 0.006660922 | 0.003728466 | 0.002057246 | 0.002173835 | 0.002469174 | 0.002856013 | 0.003233263 | 0.00364085 | 0.004378704 | 0.005298477 | 0.005887863 | 0.42% |
Manufacturing technology | 0.00307716 | 0.003196561 | 0.003330461 | 0.003389515 | 0.001870223 | 0.001086917 | 0.001234587 | 0.001428007 | 0.001616631 | 0.001820425 | 0.002189352 | 0.002649239 | 0.002943931 | 0.23% |
Therapeutic alternative | 0.106162012 | 0.110281337 | 0.114900898 | 0.116938252 | 0.117314019 | 0.068179368 | 0.042593244 | 0.049266229 | 0.055773779 | 0.062804658 | 0.075532637 | 0.091398732 | 0.101565636 | 8.56% |
Sci. evid. Clin.eff | 0.169243788 | 0.175810828 | 0.183175345 | 0.1864233 | 0.187022349 | 0.197621357 | 0.12345868 | 0.078540365 | 0.088914719 | 0.100123368 | 0.120414348 | 0.145708124 | 0.161916232 | 14.76% |
Benefits from use of medicine (safety aspects) | 0.13385645 | 0.139050382 | 0.144875045 | 0.147443882 | 0.147917676 | 0.156300528 | 0.177535622 | 0.112942343 | 0.07032346 | 0.079188482 | 0.095236803 | 0.11524188 | 0.12806102 | 12.68% |
Cost effectiveness analysis | 0.095391953 | 0.099093376 | 0.103244285 | 0.105074951 | 0.105412597 | 0.111386583 | 0.126519639 | 0.146341176 | 0.091119217 | 0.056433171 | 0.067869905 | 0.082126397 | 0.091261876 | 9.86% |
Budget impact analysis | 0.090776214 | 0.094298535 | 0.098248594 | 0.099990679 | 0.100311987 | 0.10599691 | 0.120397721 | 0.139260151 | 0.157654949 | 0.09764097 | 0.064585878 | 0.078152539 | 0.086845979 | 10.26% |
Therapy cost | 0.14154935 | 0.147041783 | 0.153201197 | 0.155917669 | 0.156418692 | 0.165283317 | 0.187738819 | 0.217151422 | 0.245834836 | 0.276824938 | 0.183109422 | 0.121864976 | 0.135420848 | 17.60% |
HTA recommendations issued elsewhere | 0.086160474 | 0.089503694 | 0.093252903 | 0.094906407 | 0.095211378 | 0.100607237 | 0.114275803 | 0.132179126 | 0.149638596 | 0.168502136 | 0.202650744 | 0.13487033 | 0.082430082 | 11.88% |
Rationalization analysis | 0.030771598 | 0.031965605 | 0.033304608 | 0.033895145 | 0.034004063 | 0.035931156 | 0.040812787 | 0.047206831 | 0.053442356 | 0.060179334 | 0.072375266 | 0.087578136 | 0.053526027 | 4.73% |
SUM | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 100.00% |